DiNAQOR
Pf├ñffikon · Founded 2019
About DiNAQOR
DiNAQOR is a gene therapy platform company that focuses on advancing novel solutions for patients suffering from heart disease. The company's novel and innovative gene therapy platform is focused on advancing treatments for patients affected by genetic cardiomyopathies, a disease of the heart muscle that can lead to heart failure. Its lead preclinical program, DiNA-001, is focused on the treatment of MYBPC3-linked cardiomyopathy. DiNAQOR was founded in 2019 and is headquartered in Pfäffikon, Switzerland.
Company Facts
- Founded: 2019
- Legal name: DiNAQOR AG
- Operating status: Operating
- Company type: For Profit
- IPO status: Private
- Employees: 1 – 10
- Estimated revenue: $1K – $10K
- Website: dinaqor.com
Social Profiles
Canonical: https://fsome.com/organization/dinaqor-8293466 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.